Immunocore Holdings (IMCR) Notes Payables (2019 - 2024)
Immunocore Holdings' (IMCR) quarterly Notes Payables came in at $48.2 million in Q3 2024, up 95.72% quarter-over-quarter from $24.6 million in Q4 2019.
Immunocore Holdings (IMCR) Notes Payables (2019 - 2024) Analysis & Trends
Immunocore Holdings has disclosed Notes Payables across 2 years of filings, most recently posting $48.2 million for Q3 2024.
- Notes Payables for Q3 2024 came in at $48.2 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $48.2 million (changed N/A YoY), and the FY2019 annual result was $24.6 million, changed N/A from the prior year.
- Notes Payables came in at $48.2 million for Q3 2024 at Immunocore Holdings, up from $24.6 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $48.2 million in Q3 2024 to a low of $48.2 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 2 | Belite Bio | 55,234.00 Bn | 55,234.00 Bn | - |
| 3 | Quantum Biopharma | 17,823.14 Bn | 17,823.14 Bn | - |
| 4 | Legend Biotech | 3,624.50 Bn | 3,624.21 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,745.73 Bn | 1,745.73 Bn | - |
| 6 | Evaxion A | 1,540.85 Bn | 1,540.84 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.57 Bn | 105.33 Bn | 2.59 Bn |
| 9 | Abivax | 93.46 Bn | 93.46 Bn | - |
| 10 | Immunocore Holdings | 1.46 Bn | 616.35 Mn | 106.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 48.21 Mn |
| Dec 31, 2019 | 24.63 Mn |